I have seen first-hand how the drug pricing dynamic has become increasingly byzantine, limiting access to important drugs for many patients who need them most. EQRx is poised to bring equity, trust and transparency back to the industry through a new approach to lowering prices without compromising quality.


Jami Rubin has spent more than 25 years as an equity analyst and banker as a partner at Goldman Sachs and PJT Partners. Jami has been ranked as a top pharmaceutical industry analyst and played a key role in significant corporate transactions with leading pharmaceutical companies including Pfizer, Abbott, AbbVie, Eli Lilly, and Mylan. Jami serves as an Independent Board Member of Relay Therapeutics and Gilda’s Club NYC and holds a BA in History from Vassar College. 

View All